FIELD: biotechnology.
SUBSTANCE: method of treating a malignant neoplasm in a mammal is described, comprising administering an effective amount of a liquid pharmaceutical composition of an anti-human PD-1 antibody. This method comprises 25-100 mg/ml of anti-human PD-1 antibody; about 70 mg/ml of sucrose; approximately 0.2 mg/ml of polysorbate 80; and approximately 10 mM of histidine buffer at pH of 5.0-6.0, where the human anti-PD-1 antibody comprises: a light chain comprising three CDR sequences of SEQ ID NO: 15.016 and 17; and a heavy chain comprising three CDR sequences of SEQ ID NOs: 18, 19 and 20. In one embodiment, the human anti-PD-1 antibody comprises: a light chain comprising amino acid residues of 20-237 of SEQ ID NO: 36 and a heavy chain comprising amino acid residues of 20-466 of SEQ ID NO: 31.
EFFECT: invention extends the arsenal by treating malignant neoplasms in mammals using an anti-human PD-1 antibody.
5 cl, 18 dwg, 3 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENT METHODS | 2012 |
|
RU2563346C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| NOVEL ANTI-PD-L1 ANTIBODIES | 2016 |
|
RU2736151C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| ANTI-HUMAN 4-1BB ANTIBODIES AND USE THEREOF | 2018 |
|
RU2725811C1 |
| ANTIBODIES AGAINST HUMAN 4-1BB AND THEIR USE | 2018 |
|
RU2777573C2 |
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2776121C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2744959C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
